89bio
San Francisco
About 89bio
89bio is a biopharmaceutical company that develops clinical-stage therapies. The company focuses on creating medicines for patients with liver and cardiometabolic diseases. Its research uses knowledge of FGF21 as a metabolic regulator to develop therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $500K – $1M
- Total funding: $1.2B
- Funding stage: M&A
- Last round: Post-IPO Equity (Jan 2025)
- Ticker: nasdaq:ETNB
- Website: 89bio.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/89bio-86941 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.